Table 2 Antiviral treatment, complications and risk of death in patients with community-acquired and nosocomial influenza, Catalonia (Spain)
Variables | Hospital acquired (N = 96) | Community acquired (N = 1626) | Crude OR (95% CI) | P value |
|---|---|---|---|---|
Antiviral treatment | ||||
Yes | 89 (92.7%) | 1485 (91.3%) | 1.06 (0.48–2.34) | 0.89 |
No | 7 (7.3%) | 141 (8.7%) | Ref. | |
Antiviral treatment | ||||
≤ 48 h before symptom onset | 62 (67.4%) | 375 (23.9%) | 2.94 (1.30–6.66) | 0.01 |
> 48 h before symptom onset | 23 (25.0%) | 1051 (67.1%) | 0.42 (0.18–1.00) | 0.05 |
No | 7 (7.6%) | 141 (9.0%) | Ref. | |
Hospital stay; median (range) | 13 (2–76) | 9 (0–137) | 0.001 | |
Hospital stay | ||||
0–14 days | 55 (57.3%) | 1174 (72.3%) | Ref. | |
> 14 days | 41 (42.7%) | 450 (27.7%) | 2.04 (1.33–3.14) | < 0.001 |
Pneumonia | ||||
Yes | 52 (54.2%) | 1237 (76.4%) | 0.34 (0.22–0.53) | < 0.001 |
No | 44 (45.8%) | 383 (23.6%) | Ref. | |
ARDS | ||||
Yes | 33 (34.4%) | 626 (39.3%) | 0.86 (0.52–1.42) | 0.57 |
No | 63 (65.6%) | 965 (60.7%) | Ref. | |
Multiorgan failure | ||||
Yes | 10 (10.6%) | 166 (10.5%) | 1.10 (0.56–2.19) | 0.78 |
No | 84 (89.4%) | 1416 (89.5%) | Ref. | |
ICU admission | ||||
Yes | 31 (32.3%) | 561 (34.5%) | 1.00 (0.64–1.56) | 0.99 |
No | 65 (67.7%) | 1065 (65.5%) | Ref. | |
Death | ||||
Yes | 18 (18.8%) | 205 (12.6%) | 1.91 (1.11–3.31) | 0.02 |
No | 78 (81.3%) | 1421 (87.4%) | Ref. | |